Back to Ophthalmology

OUR EXPERTISE AND SERVICES AVAILABLE IN

nAMD

Overview

Spherix’s coverage of the neovascular age-related macular degeneration (nAMD) market focuses on the current VEGF treatment landscape and the upcoming shift in the treatment paradigm, particularly the expansion of intravitreal biologic options, new MOAs, and introduction of biosimilars.

Services Available

Prepping for the pipeline

  • Neovascular Age-Related Macular Degeneration (US)

Exploring the patient journey

  • Treatment Switching in Neovascular Age-Related Macular Degeneration (US)

Benchmarking new brand performance

  • Faricimab (Genentech) in Age-Related Macular Degeneration (US)*

  • Byooviz (Samsung Bioepis and Biogen) Ranibizumab Biosimilar (US)

  • FYB201 (Coherus BioSciences) Ranibizumab Biosimilar (US)*

*Pending approvals and launch

Gauging impact of disruptive events

  • Market Entry of Susvimo (Genentech) – Port Delivery System in Neovascular Age-Related Macular Degeneration (US)

  • Ophthalmology Biosimilars Today and Tomorrow (US)

Learn more about our services

  • HOW CAN WE PARTNER TOGETHER?

    Get more information on Neovascular Age-Related Macular Degeneration Coverage